newdrugapprovals.org
VBL Therapeutics announced FDA has granted Fast Track designation to its lead oncology drug VB-111
GT-111 VB-111 GT-111 is a gene therapy product candidate in early clinical development for the treatment of advanced differentiated thyroid cancer, for the treatment of relapsed glioblastoma multif…